Research

The aim of this website is to provide an overview of all scientific research that is conducted worldwide on MDC1A / Lama2 CMD, as complete as possible. Do you know about any other (new) research being done? Let us know, so we can update this overview.

Involved organizations

LAMA2-CMD / MDC1A in the world

Institut de Myologie

Who: Multiple research groups
Where: Paris, France
Research: The Institut de Myologie is a reference international research centre at the heart of Europe’s largest hospital, The Pitié-Salpêtrière Hospital in Paris. Created in 1996 under the leadership of an association of patients and their parents, the AFM-Telethon, the institute carries out numerous trials and investigations into a range of muscle diseases.
 
More information can be found here.

Marseille Medical Genetics

Who: Multiple research groups
Where: Marseille , France
Research:
The research carried out at MMG aims to decipher the mechanisms involved in genetic diseases, open new diagnostic and therapeutic pathways and improve the quality of life of patients affected by these rare diseases.
Further detail can be found here.

Vall d'Hebron

Who: Dr. Francina Munell and Dr. Jordi Barquinero
Where: Barcelona, Spain
Research: Diagnostics and stem cell therapy for LAMA2-CMD patients

University Pompeu Fabra

Who: Dr. Avencia Sánchez-Mejías
Where: Barcelona, Spain
Research: Dr. Avencia Sanchez-Mejías has been investigating how stem cells from LAMA2-CMD patients’ bone marrow can be genetically corrected to potentially improve quality of life.
Further information and video presentation of her work can be found here.

Radboud University

Who: Dr. Nicol Voermans, Drs. Karlijn Bouman, Dr. Corrie Erasmus and Dr. Jan Groothuis
Where: Nijmegen, The Netherlands
Research: Researchers at Radboud University are currently running a natural history study for SELENON myopathy patients and LAMA2-CMD patients. The aim of the study is to gain a better understanding of how MDC1A progresses in patients over time and to identify suitable outcome measures in preparation for future MDC1A clinical trials.

University of Manchester

Who: Prof. Dr. G. Cossu
Where: Manchester, U.K.
Research: Dr. Giulio Cossu is recognized for his pioneering work on skeletal myogenesis and for the first cell therapy trial with stem cells for muscular dystrophy. He conducted a first in man clinical trial of cell therapy for Duchenne’s Muscular Dystrophy and is starting a second trial with genetically corrected autologous cells.

National Institutes of Health

Who: Dr. Carsten Bönnemann and Dr. Reghan Foley
Where: Maryland, U.S.A.
Research: Both Dr. Bönnemann and Dr. Foley with the NIH are working on collecting data on the progression of MDC1A / LAMA2-CMD in patients to prepare for future clinical trials and maximise the chances of potential therapeutic success. Both are collaborating with Cure CMD and running a retrospective natural history study to characterise aspects of MDC1A in young infants aged 0-5 years.

Prothelia

Who: Prothelia Therapeutics
Where: Massachusetts, U.S.A.
Research: Prothelia is a biopharmaceutical company uniquely focused on developing novel treatments for congenital muscular dystrophies. It’s lead drug program rhLAM-111 is as a protein replacement therapy for LAMA2-CMD. Prothelia is also collaborating with other partners on this map to run natural history studies that will help to establish the best clinical outcomes to include in potential future clinical trials.
More information can be found on the Prothelia website.

University of Pittsburgh

Who: Dr. Dwi Kemaledwi
Where: Pennsylvania, U.S.A.
Research: Dr. Dwi Kemaladewi has extensive training in human genetics and the development of gene therapies, with a focus on neuromuscular disorders. Her research focuses on the underlying molecular mechanisms involved in the pathophysiology of muscular dystrophies, using cutting-edge genetic technologies to study and develop therapeutic interventions for rare paediatric diseases.
Much of Dr. Kemaladewi’s recent work has involved optimising a gene therapy capable of activating the expression of a gene that can compensate for the mutated LAMA2 gene involved in LAMA2-CMD. This compensatory gene is called LAMA1 and is very similar to LAMA2. This strategy has shown positive results in early animal models of LAMA2-CMD and is described in more detail in a video presentation here.

Lund University

Who: Prof. Dr. Madeleine Durbeej
Where: Lund, Sweden
Research: Prof. Dr. Madeleine Durbeej leads the Muscle Biology unit at Lund University, Sweden, which researches laminin ɑ2 chain-deficient congenital muscular dystrophy.

Maastricht University

Who: Professor Dr. Bert Smeets
Where: Maastricht, The Netherlands
Research: Professor Dr. Bert Smeets is currently leading research investigating the use of genetically corrected muscle stem cells to treat genetic and non-genetic muscle diseases.
He is also a member of the newly formed research initiative Generate Your Muscle, which brings together a number of European research centres with the aim of to developing commercially producing affordable stem cell therapies for muscle repair and regeneration in affected individuals.

The driving forces behind Lama2.com

View all partners